Frelii (FRLI) Stock Price

Frelii Price

OTC·CLOSED
0.00USD+0.00 (+0.00 %)
Market closed

Revenue at Frelii has contracted by 18.6% per year over the past 9 years to 36,000.00 USD. For Frelii, the net margin of -15,415.8% is down versus 69.6% a few years ago.

Frelii stock price

Volume
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Frelii over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Frelii stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Frelii's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Frelii Stock Price History
DateFrelii Price
7/10/20260.00 USD
7/9/20260.00 USD
7/8/20260.00 USD
7/7/20260.00 USD
7/6/20260.00 USD
7/2/20260.00 USD
7/1/20260.00 USD
6/30/20260.00 USD
6/29/20260.00 USD
6/26/20260.00 USD
6/25/20260.00 USD
6/24/20260.00 USD
6/23/20260.00 USD
6/22/20260.00 USD
6/18/20260.00 USD
6/17/20260.00 USD
6/16/20260.00 USD
6/15/20260.00 USD
6/12/20260.00 USD
6/11/20260.00 USD
6/10/20260.00 USD
6/9/20260.00 USD
6/8/20260.00 USD
6/5/20260.00 USD
6/4/20260.00 USD
6/3/20260.00 USD
6/2/20260.00 USD
6/1/20260.00 USD
5/29/20260.00 USD
5/28/20260.00 USD
5/27/20260.00 USD
5/26/20260.00 USD
5/22/20260.00 USD
5/21/20260.00 USD
5/20/20260.00 USD
5/19/20260.00 USD
5/18/20260.00 USD
5/15/20260.00 USD
5/14/20260.00 USD
5/13/20260.00 USD
5/12/20260.00 USD
5/11/20260.00 USD
5/8/20260.00 USD
5/7/20260.00 USD
5/6/20260.00 USD
5/5/20260.00 USD
5/4/20260.00 USD
5/1/20260.00 USD
4/30/20260.00 USD
4/29/20260.00 USD
4/28/20260.00 USD
4/27/20260.00 USD
4/24/20260.00 USD
4/23/20260.00 USD
4/22/20260.00 USD
4/21/20260.00 USD
4/20/20260.00 USD
4/17/20260.00 USD
4/16/20260.00 USD
4/15/20260.00 USD
4/14/20260.00 USD
4/13/20260.00 USD
4/10/20260.00 USD
4/9/20260.00 USD
12/29/20250.00 USD
12/4/20250.00 USD
11/24/20250.00 USD
11/17/20250.00 USD
11/12/20250.00 USD
11/4/20250.00 USD
10/31/20250.00 USD
Access this data via the Eulerpool API

Frelii Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2011
0.00 USD
-1.05 M USD
-2.21 M USD
Jan 1, 2012
0.00 USD
-190,000.00 USD
-270,000.00 USD
Jan 1, 2013
0.00 USD
-178,600.00 USD
-246,800.00 USD
Jan 1, 2014
0.00 USD
-181,800.00 USD
-269,600.00 USD
Jan 1, 2015
0.00 USD
-186,500.00 USD
-274,000.00 USD
Jan 1, 2016
0.00 USD
-183,400.00 USD
-271,000.00 USD
Jan 1, 2017
0.00 USD
-225,900.00 USD
595,500.00 USD
Jan 1, 2018
36,000.00 USD
-4.26 M USD
-5.55 M USD

Frelii Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 14, 2026, 12:53 AM
 
NET INCOMEM USD
SHARESM
2006200720082009201020112012201320142015201620172018
-2.00-5.00
35.4335.430.010.100.100.110.090.091.941.941.949.3035.43
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Frelii generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Frelii retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Frelii's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Frelii has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Frelii's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Frelii stock margins

The Frelii margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Frelii. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Frelii.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2011
22.50 %
- %
- %
Jan 1, 2012
22.50 %
- %
- %
Jan 1, 2013
22.50 %
- %
- %
Jan 1, 2014
22.50 %
- %
- %
Jan 1, 2015
22.50 %
- %
- %
Jan 1, 2016
22.50 %
- %
- %
Jan 1, 2017
22.50 %
- %
- %
Jan 1, 2018
22.50 %
-11,829.72 %
-15,415.83 %

Frelii Stock Revenue, EBIT, Earnings per Share

The Frelii earnings per share therefore indicates how much revenue Frelii has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2011
0.00 USD
-9.55 USD
-20.09 USD
Jan 1, 2012
0.00 USD
-2.11 USD
-3.00 USD
Jan 1, 2013
0.00 USD
-1.99 USD
-2.75 USD
Jan 1, 2014
0.00 USD
-0.09 USD
-0.14 USD
Jan 1, 2015
0.00 USD
-0.10 USD
-0.14 USD
Jan 1, 2016
0.00 USD
-0.09 USD
-0.14 USD
Jan 1, 2017
0.00 USD
-0.02 USD
0.06 USD
Jan 1, 2018
0.00 USD
-0.12 USD
-0.16 USD

Frelii business model & stock analysis

Frelii Inc is an emerging company in the field of personalized healthcare and diagnostics. The company, which opened its headquarters in Salt Lake City, Utah, USA in 2016, aims to provide personalized therapies and diagnoses for each patient based on DNA tests and computer analysis. The company has a specialized team of scientists, doctors, engineers, and IT experts who have come together to develop advanced technologies that have the potential to revolutionize healthcare. Business model: Frelii's business model is focused on providing personalized diagnoses and therapies for each patient. The company can achieve this through a combination of DNA testing, genome data analysis, and the use of AI algorithms. With a wide range of tests and analyses, Frelii can unleash the full potential of high-tech diagnostics and minimally invasive therapy. History: The company was founded by CEO Ian Jenkins and Dr. David R. Koepsell (formerly President of Upturn). Their goal was to decipher the human genome and use the results of genome tests to provide precise diagnoses and therapies. Since then, the company has focused on understanding the complexity of the human genome and maximizing the capabilities of personalized medicine and diagnostics. Offered divisions and products: Frelii offers a range of personalized DNA tests and analyses. These tests examine an individual's entire genome to gain information about personal risks for diseases, allergies, and other medical conditions. These results are then analyzed by a team of scientists and doctors who create personalized recommendations for diet, lifestyle, and medical therapy. Frelii also has its own software platform for processing genome data and offers personalized research and development programs for clinical studies, association analyses, and genome-wide screens. The company is also a leader in the development of therapy and diagnostic methods based on CRISPR/Cas9 and other high-tech technologies. The Frelii team is committed to improving the quality of medical care and facilitating access to personalized healthcare methods. Frelii's DNA tests have already led to a variety of patients being able to discover their disease risks for themselves and consciously engage in adapting their lifestyles. The company aims to bring research efforts and the practical implementation of personalized medicine to the forefront. Conclusion: Frelii is at the forefront of personalized genomic research and aims to take healthcare to a whole new level. The company offers personalized DNA tests and analyses, as well as the analysis of genome data to provide precise diagnoses and therapies. Frelii has its own software platform for processing genome data that engages medical researchers, doctors, and patients alike. It remains to be seen how this emerging company will redefine personalized medical care.

Frelii SWOT Analysis

Strengths

Frelii Inc possesses various strengths that contribute to its competitive advantage in the market. One of the key strengths is its advanced technology platform, which incorporates artificial intelligence and machine learning algorithms. This enables the company to efficiently analyze and interpret large amounts of genetic data, providing valuable insights to its clients.

Another strength is Frelii's extensive network of partnerships and collaborations with renowned research institutions and genetic testing laboratories. By leveraging these relationships, Frelii gains access to diverse genetic data sets and expertise, enhancing the accuracy and reliability of its genetic analysis services.

Additionally, the company benefits from a highly experienced and knowledgeable team of scientists, researchers, and geneticists. Their expertise in genomics and data analysis allows Frelii to continually improve and innovate in its field, staying ahead of competitors.

Weaknesses

Despite its strengths, Frelii Inc also faces certain weaknesses that can hinder its growth and market position. One weakness is the reliance on external partnerships for access to genetic data. This dependency may limit the company's control over data availability and introduce potential delays or complications in data acquisition, affecting service delivery timelines.

Another weakness is the high initial cost associated with implementing Frelii's technology platform and infrastructure. This can discourage some potential clients, particularly smaller research institutions or healthcare providers with limited budgets, from adopting Frelii's genetic analysis services.

Furthermore, the complex nature of genomic analysis and interpretation may also pose a challenge as it requires highly specialized knowledge. Frelii needs to ensure that its platform is user-friendly and provides comprehensive support and training to its clients to overcome this weakness effectively.

Opportunities

Frelii Inc operates in an industry that offers several potential opportunities for growth and market expansion. One significant opportunity is the increasing demand for personalized medicine and precision healthcare. As genomics becomes more integrated into healthcare, Frelii can capitalize on this trend by providing genetic analysis services that help tailor treatment plans and preventive measures to individual patients.

Moreover, the expanding global market for genetic testing and analysis presents an opportunity for Frelii to penetrate new geographical regions and target diverse customer segments. By adapting its technology to different markets and complying with local regulations, the company can expand its customer base and revenue streams.

Additionally, collaborations with pharmaceutical companies and biotech firms could open doors for Frelii to participate in cutting-edge research and development projects. Such partnerships can lead to the identification of novel biomarkers, the advancement of genomic therapies, and the discovery of new drug targets.

Threats

Frelii Inc faces several threats that could impact its business operations and market position. One of the threats is the presence of well-established competitors in the genomics industry. These competitors often have brand recognition, extensive resources, and established customer relationships, posing a barrier to entry for new players like Frelii.

Additionally, the evolving regulatory landscape surrounding genomic data privacy and protection presents a threat to Frelii's operations. Compliance with varying regulations in different jurisdictions requires significant resources and expertise. Failure to comply adequately may result in legal and reputational consequences for the company.

Lastly, the potential emergence of alternative technologies or scientific breakthroughs in genomics could render Frelii's current offerings obsolete or less competitive. Continuous investment in research and development is crucial for adapting to changing market dynamics and staying at the forefront of innovation.

Frelii Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Frelii historical P/E ratio, EBIT multiple, and P/S ratio

Frelii annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Frelii shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2011
110,000.00 Stocks
Jan 1, 2012
90,000.00 Stocks
Jan 1, 2013
89,800.00 Stocks
Jan 1, 2014
1.94 M Stocks
Jan 1, 2015
1.94 M Stocks
Jan 1, 2016
1.94 M Stocks
Jan 1, 2017
9.30 M Stocks
Jan 1, 2018
35.43 M Stocks

Frelii stock splits

In Frelii's history, there have been no stock splits.
Price targets and forecasts for Frelii are not yet available.

Frelii shareholder structure

% Name
0.00000%
Kohmann Bosshard Financial Services, LLC
Kohmann Bosshard Financial Services, LLC

Frelii Executives and Management Board

IJ

Mr. Ian Jenkins

Chief Executive Officer, Chief Financial Officer, Director · since 2017

SU

Mr. Sandeep Uppal

Chief Administrative Officer

HJ

Dr. Hans Jenkins

Director, Chief Medical Officer

LN

Ms. Leslie Norris

Director · since 2018

Frequently asked questions about Frelii

Frelii Inc operates under a unique business model that combines advanced genetics, artificial intelligence, and big data analytics. The company focuses on providing personalized precision medicine and healthcare solutions to individuals. Frelii utilizes its proprietary DNA sequencing platform to uncover genetic insights and form comprehensive health profiles. By leveraging the power of AI and vast amounts of data, Frelii analyzes this information to offer tailored treatment plans, preventive measures, and lifestyle recommendations. This innovative approach enables individuals to make informed decisions about their health and well-being, improving overall outcomes. Frelii Inc's business model seamlessly integrates cutting-edge technology with the realm of healthcare to deliver personalized and optimized solutions.

All fundamentals and in-depth analysis of Frelii

Our stock analysis for Frelii stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Frelii. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.